Intimation of Phase III Clinical Trial of DengiAll by ICMR and Panacea Biotec

Reclassification of Promoter and Promoters Group

Change in Auditor of Material Subsidiary, Panacea Biotec Pharma Ltd.

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)

Receipt of request for arbitration filed by Human Vaccine

Closure of Trading Window w.e.f. July 01, 2024

Incorporation of wholly owned subsidiary of PBPL in US

Intmation regarding change in Senior Management Personnel of the Company’s material subsidiary viz. Panacea Biotec Pharma Limited

Related Party Transactions for half year ended March 31, 2024

Change in designation of Mr. Ankesh Jain